Ceribell Inc (CBLL) Stock Forecast & Price Target

CeriBell is viewed positively because its core point-of-care EEG platform is already driving near-30% sales growth, with Q2 beating expectations, gross margin at 92.3%, and 712 active hospital accounts while penetration remains under 4% of the core seizure market. Its outlook is strengthened by multiple growth vectors: pediatric/neonate approvals that expanded total addressable market to more than $3.5 billion, a delirium launch with CMS NTAP support, and a stroke program with FDA breakthrough designation. Management also has a durable moat from AI and hardware upgrades, improving salesforce productivity, and low competition, supporting confidence in continued utilization gains and a path toward break-even.

CeriBell is exposed to meaningful supply-chain and margin risk because a significant further increase in tariffs on imports from China, or a ban on Chinese imports, could force greater sourcing from Vietnam and pressure gross margins. This dependence on imported components creates vulnerability to policy shifts that are outside management’s control, making cost structure less predictable and potentially impairing profitability even if demand for its products remains healthy. The repeated emphasis on this risk suggests a material operational overhang that could weigh on financial performance and investor confidence.